Melanoma & Skin Cancer

The combination of atezolizumab (Tecentriq) and cobimetinib (Cotellic) did not improve progression-free survival compared with pembrolizumab (Keytruda) in patients with previously untreated BRAF V600 wild-type melanoma, missing the primary endpoint of the phase III IMspire170 trial.

Caroline Robert, MD, PhD, head of the Dermatology Unit in Gustave Roussy Cancer Center, Villejuif-Paris, France, discusses results of a 5-year analysis evaluating the long-term effects of dabrafenib (Tafinlar) and trametinib (Mekinist) in patients with BRAF V600–mutant unresectable or metastatic melanoma.

Douglas B. Johnson, MD, assistant professor of medicine, Vanderbilt University Medical Center, clinical director, Melanoma Research Program, Vanderbilt-Ingram Cancer Center, discusses applications of immunotherapy in melanoma.

The use of immunotherapy in cancer was solidified by the ample activity seen in patients with melanoma.

Adil Daud, MD, clinical professor, Department of Medicine, director, Melanoma Clinical Research, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the immunogenicity of melanoma.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.